Clinical Trial Information A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation Protocol Number: 70033093AFL3002 Status: Open Age Group: Adult Treatment Type: Treatment Secondary Protocol No.: JNJ-70033093 Phase: III NCT ID: NCT05757869 Scope Information Disease Site(s): Other
